Dr. Reddy’s enters pact to distribute Amgen’s three drugs in India

Dr. Reddy’s will commercialize Amgen’s osteoporosis drugs XGEVA and Prolia, and cancer drug Vectibix in India


In 2015, Dr. Reddy’s had announced an initial strategic collaboration with Amgen . Photo: Mint
In 2015, Dr. Reddy’s had announced an initial strategic collaboration with Amgen . Photo: Mint

Hyderabad: Dr. Reddy’s Laboratories Ltd on Friday said it had expanded its collaboration with US-based Amgen Inc to market and distribute three of the biotech major ’s oncology and osteoporosis medicines in India.

Under the collaboration, Dr. Reddy’s will commercialize Amgen’s osteoporosis drugs XGEVA and Prolia, and cancer drug Vectibix in India. All the three drugs have been approved in India.

“These medicines provide unique treatment options to physicians to address unmet medical need in the area of oncology and osteoporosis,” said M.V.Ramana, executive vice-president and head of emerging markets and India business at Dr. Reddy’s.

In 2015, Dr. Reddy’s had announced an initial strategic collaboration with Amgen for a full range of regulatory and commercial services to launch the US company’s cancer drugs Kyprolis and Blincyto, and cardiovascular drug Repatha in India.

Dr.Reddy’s shares were up 0.07% at Rs.3145.80 on the Bombay Stock Exchange at 3.20 pm. The benchmark Sensex was 0.61% higher at 28,587.03 points.

Sponsored Links by Revcontent